General Information of Drug Combination (ID: DCGX3N2)

Drug Combination Name
MK-5108 RTB101
Indication
Disease Entry Status REF
Adenocarcinoma Investigative [1]
Component Drugs MK-5108   DMFGYKS RTB101   DM62QTW
Small molecular drug Small molecular drug
High-throughput Screening Result Testing Cell Line: CAOV3
Zero Interaction Potency (ZIP) Score: 4.62
Bliss Independence Score: 5.27
Loewe Additivity Score: 7.06
LHighest Single Agent (HSA) Score: 11.05

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of MK-5108
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
MK-5108 Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Aurora kinase B (AURKB) TT5LS6T AURKB_HUMAN Inhibitor [5]
Aurora kinase A (AURKA) TTPS3C0 AURKA_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------
Indication(s) of RTB101
Disease Entry ICD 11 Status REF
Respiratory tract infection CA45 Phase 3 [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [4]
RTB101 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
CREB-regulated transcription coactivator 1 (TORC1) TT4GO0F CRTC1_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Ewing sarcoma-peripheral primitive neuroectodermal tumour DCTOAFZ ES2 Investigative [7]
Breast and ovarian cancer syndrome DCPWM10 UWB1289 Investigative [8]
Breast and ovarian cancer syndrome DCI8VGW UWB1289+BRCA1 Investigative [8]
Breast carcinoma DCJ0R7O OCUBM Investigative [8]
Carcinoma DC0MBUE EFM192B Investigative [8]
Carcinoma DCJSAE3 MDAMB436 Investigative [8]
Colon adenocarcinoma DCG5Z5Q LOVO Investigative [8]
Invasive ductal carcinoma DCPB7L4 T-47D Investigative [8]
Adenocarcinoma DC38E6Y A427 Investigative [1]
Adenocarcinoma DC3ZAIZ NCIH2122 Investigative [1]
Adenocarcinoma DCWSQJO NCIH520 Investigative [1]
Adenocarcinoma DCFXDSX HT29 Investigative [1]
Amelanotic melanoma DC2YLWS A2058 Investigative [1]
Germ cell tumour DC6RGCD PA1 Investigative [1]
Malignant melanoma DCNKF7S HT144 Investigative [1]
Malignant melanoma DCJT0W2 RPMI7951 Investigative [1]
Malignant melanoma DCHAO2N SKMEL30 Investigative [1]
Malignant melanoma DCD44TR UACC62 Investigative [1]
Mesothelioma DCSM853 MSTO Investigative [1]
Non small cell carcinoma DCZEFPF SKMES1 Investigative [1]
Ovarian endometrioid adenocarcinoma DCHAJJC A2780 Investigative [1]
Prostate carcinoma DC9I9LM VCAP Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 22 DrugCom(s)

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 ClinicalTrials.gov (NCT00543387) Treatment of Participants With Advanced and/or Refractory Solid Tumors (MK-5108-001 AM4). U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT04139915) Effect of RTB101 on Illness Associated With Respiratory Tract Infections in the Elderly. U.S. National Institutes of Health.
4 ClinicalTrials.gov (NCT04409327) Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes. U.S. National Institutes of Health.
5 A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
6 Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.
7 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
8 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.